Nasdaq:COSM
Cosmos Health Inc.
Cosmos Health develops and markets innovative CT scanners that significantly reduce patient radiation doses for hospitals across North America.
Key Metrics
Investment Thesis
Bull Case
Investors may view COSM as a high-risk turnaround play with strong intellectual property moats that could yield monopoly-like pricing power if they can secure additional financing. The consistent year-over-year revenue growth and narrowing net losses demonstrate an improving operational trajectory that could attract strategic acquirers in the medical device space.
Bear Case
The stock carries substantial bearish risk given the massive retained earnings deficit of $114M and negative operating cash flow which limits flexibility for R&D or marketing expansion. With current liabilities exceeding current assets, the company's liquidity position is fragile, making it highly susceptible to interest rate hikes or a downturn in hospital capital expenditure.
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ: COSM) is a leading provider of advanced medical imaging solutions, primarily serving hospitals and healthcare systems in the United States through its proprietary CT scanner technology. The company focuses on reducing patient radiation exposure while delivering high-quality diagnostic images, operating in the competitive medical device market.
Analysis
Management Discussion
Despite a revenue increase from $50.3M in 2022 to $54.4M in 2024, the company continues to report substantial net losses, improving only marginally from -$63.9M in 2022 to -$16.2M recently. The narrowing loss suggests potential efficiency gains or stabilization in sales, but cash flow from operations remains negative at $7.7M while ending cash reserves have depleted significantly to just $315K.
Industry Overview
The medical imaging industry is dominated by large multinational corporations with massive R&D budgets and global distribution networks, creating a high barrier to entry for small innovators. While the trend toward radiation-reduction technology is favorable for niche players, the competitive landscape remains challenging for companies without significant scale or established market share.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $50.3M | $53.4M | $54.4M |
| Cost of Revenue | $44.4M | $49.0M | $50.1M |
| Gross Profit | $6.0M | $4.3M | $4.3M |
| Operating Expenses | $13.4M | $26.2M | $19.9M |
| Operating Income | $-7.5M | $-21.8M | $-15.5M |
| R&D | — | — | $533.3K |
| G&A | $10.2M | $19.6M | $11.7M |
| Marketing | $630.1K | $1.2M | $355.0K |
| Stock-Based Comp | $24.4K | $577.9K | $1.7M |
| D&A | $103.2K | $614.4K | $1.2M |
| Depreciation | $70.1K | $353.0K | $387.0K |
| Amortization | $33.1K | $239.8K | $793.8K |
| Other OpEx | $2.6M | $5.0M | $6.9M |
| Non-Operating Income | $-5.6M | $3.3M | $-638.2K |
| Interest Expense | $2.3M | $866.5K | $1.0M |
| Interest Income | $236.3K | $662.9K | $406.4K |
| Pre-Tax Income | $-13.1M | $-18.5M | $-16.2M |
| Income Tax | $775.1K | $0 | $0 |
| Continuing Ops | $-13.8M | $-18.5M | $-16.2M |
| Discontinued Ops | $-50.1M | $0 | $0 |
| Net Income | $-63.9M | $-18.5M | $-16.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-63.9M | $-18.5M | $-16.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $56.0M | $36.6M | $25.5M |
| Cash & Equivalents | $20.7M | — | — |
| Marketable Securities | $14.9K | $20.1K | $21.1K |
| Accounts Receivable | — | $19.8M | $13.5M |
| Inventory | $3.5M | $4.8M | $4.4M |
| Prepaid Expenses | $2.0M | $1.8M | $1.3M |
| Other Current Assets | $29.9M | $10.2M | $6.3M |
| Long-Term Assets | $12.0M | $29.4M | $28.9M |
| PP&E (Net) | $1.8M | $10.5M | $9.7M |
| Intangibles | $657.2K | $7.6M | $7.7M |
| Goodwill | $49.7K | $49.7K | $49.7K |
| Operating Leases | $821.1K | $1.1M | $696.2K |
| Other LT Assets | $8.6M | $10.1M | $10.7M |
| Total Assets | $68.0M | $66.0M | $54.3M |
| Current Liabilities | $21.7M | $24.3M | $25.8M |
| Current Leases | $167.4K | $285.6K | $196.7K |
| Other Current Liab | $21.3M | $23.9M | $25.3M |
| Long-Term Liabilities | $6.6M | $5.6M | $4.0M |
| LT Operating Leases | $653.7K | $844.9K | $498.4K |
| Other LT Liab | $6.0M | $-1.8M | $-3.5M |
| Total Liabilities | $28.4M | $30.0M | $29.8M |
| Shareholders' Equity | $39.3M | $36.0M | $24.5M |
| Paid-In Capital | $112.2M | $129.0M | $141.6M |
| Retained Earnings | $-66.2M | $-91.6M | $-114.0M |
| AOCI | $-1.1M | $-419.8K | $-2.1M |
| Treasury Stock | $816.7K | $917.2K | — |
| Total L&E | $68.0M | $66.0M | $54.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-63.9M | $-18.5M | $-16.2M |
| Non-Cash Adjustments | $43.4M | $-1.4M | $7.6M |
| Working Capital Changes | $5.7M | $4.3M | $844.6K |
| Cash from Operations | $-14.9M | $-15.6M | $-7.7M |
| Capital Expenditures | $74.2K | $1.3M | $418.1K |
| Cash from Investing | $-21.5K | $-13.8M | $-798.3K |
| Share Buybacks | — | $100.5K | $0 |
| Cash from Financing | $35.0M | $12.7M | $5.0M |
| FX Effect | $307.0K | $-214.1K | $-49.5K |
| Net Change in Cash | $20.5M | $-16.9M | $-3.5M |
| Beginning Cash | $286.5K | $20.7M | $3.8M |
| Ending Cash | $20.7M | $3.8M | $315.1K |
Frequently Asked Questions
How does Cosmos Health Inc. make money?
The company's revenue is primarily derived from the sale and lease of its proprietary compact Computed Tomography (CT) scanners. Additional segments include service contracts, spare parts sales, and software licensing fees associated with their imaging technology ecosystem.
What are the main risks for COSM?
The company faces significant concentration risk as a small-cap entity with limited market share against established industry giants. Operating losses of $16.2M and a retained earnings deficit of $114.0M indicate ongoing cash flow challenges that could threaten solvency if financing dries up. Dependence on a single product line makes the business vulnerable to regulatory changes in radiation safety standards.
What is COSM's competitive advantage?
Cosmos holds a unique patent portfolio for ultra-low radiation CT technology that differentiates it from major competitors like GE and Siemens. The company's specialized niche in reducing patient exposure creates high switching costs for healthcare providers who have already integrated its specific imaging protocols into their workflows.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.